
Alzamend Neuro Inc
Monthly Stock Prices Chart
This stock price chart for Alzamend Neuro Inc, symbol ALZN, Nasdaq Stock Exchange is updated
monthly. TradingCharts.com offers over 30 thousand free stock price charts and stock market quotes.
[Add symbol to "MyMenu"]
Daily and Weekly charts are also available for Alzamend Neuro Inc.
Most Recent HeadlinesPRS: Mar 13th, 2025, 15:05Length: 1056 Alzamend Neuro Sets Stage for Phase II Clinical Trial of AL001 Targeting Post-Traumatic Stress Disorder at Massachusetts General Hospital
PRS: Mar 13th, 2025, 14:35Length: 1056 Alzamend Neuro Sets Stage for Phase II Clinical Trial of AL001 Targeting Post-Traumatic Stress Disorder at Massachusetts General Hospital
PRS: Mar 13th, 2025, 14:05Length: 1056 Alzamend Neuro Sets Stage for Phase II Clinical Trial of AL001 Targeting Post-Traumatic Stress Disorder at Massachusetts General Hospital
PRS: Mar 13th, 2025, 13:35Length: 1056 Alzamend Neuro Sets Stage for Phase II Clinical Trial of AL001 Targeting Post-Traumatic Stress Disorder at Massachusetts General Hospital
PRS: Mar 13th, 2025, 13:05Length: 1056 Alzamend Neuro Sets Stage for Phase II Clinical Trial of AL001 Targeting Post-Traumatic Stress Disorder at Massachusetts General Hospital
PRS: Mar 13th, 2025, 13:00Length: 1056 Alzamend Neuro Sets Stage for Phase II Clinical Trial of AL001 Targeting Post-Traumatic Stress Disorder at Massachusetts General Hospital
PRS: Mar 13th, 2025, 12:30Length: 1056 Alzamend Neuro Sets Stage for Phase II Clinical Trial of AL001 Targeting Post-Traumatic Stress Disorder at Massachusetts General Hospital
PRS: Mar 13th, 2025, 12:10Length: 1056 Alzamend Neuro Sets Stage for Phase II Clinical Trial of AL001 Targeting Post-Traumatic Stress Disorder at Massachusetts General Hospital
PRS: Mar 13th, 2025, 11:40Length: 1056 Alzamend Neuro Sets Stage for Phase II Clinical Trial of AL001 Targeting Post-Traumatic Stress Disorder at Massachusetts General Hospital
PRS: Mar 13th, 2025, 11:10Length: 1056 Alzamend Neuro Sets Stage for Phase II Clinical Trial of AL001 Targeting Post-Traumatic Stress Disorder at Massachusetts General Hospital
|